当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Rabindran, Devendran V and Velmurugan D
Antibiotic resistance is a serious problem in the management of childhood infections. Bacteria have developed various mechanisms of resistance. Indiscriminate and irrational use of antibiotics have led to the emergence of superbugs which have developed resistance to multiple antibiotics. Nowadays research are showing promising role of usage of older antibiotics for treatment of resistant infections. Multidrug resistant gram negative infections is a challenging situation where combination therapy and drugs with gram positive coverage like vancomycin are showing positive results. Ampicillin is losing sensitivity and protocols have been modified in using cephalosporins as the first line in some units. Carbapenam resistance and ESBL are emerging among hospitalised patients. Similarly emergence of community acquired MRSA possessing a new virulence toxin (Panton-Valentine leukocidin) is a serious threat among childhood infections. Unfortunately of late only minimal resources are directed to the development of newer antibiotics. Its time to consider the emerging antibiotic resistance particularly among children as a serious issue and start rational antibiotic practice and develop unit specific antibiotic policy to fight against antibiotic resistance.